The following is the summary of “Novel Regimen of IL-17A Inhibitor Secukinumab for the Remission of Severe Hidradenitis Suppurativa: Case Report” published in the December 2022 issue of Dermatology by Gutierrez, et al.
Hidradenitis suppurativa, often known as HS, is a persistent skin condition that has the potential to be lethal and presents a considerable challenge to therapeutic therapy. According to studies that investigated the mechanisms that led to the development of hypersensitivity syndrome (HS), the progression and severity of the condition are largely determined by a number of factors, one of which is the presence of local and systemic pro-inflammatory cytokines.
In particular, TNF- and IL-17A. As a direct consequence of this, the treatment for HS has undergone a revolution due to the development of biologics that specifically target these cytokines. Researchers discuss the example of a guy in his thirties who was found to have considerable Hurley Stage 3 HS unresponsive to treatment. Following several unsuccessful clinical trials of topical, systemic, and biologic therapies, a treatment with secukinumab that consists of 150 mg weekly injections were initiated.
Clinical response to HS was detected after 20 weeks of treatment and was maintained for nearly 2 years. Once weekly dosage of secukinumab 150 mg or 300 mg may be an effective and safe therapeutic approach for people who have moderate to severe chronic HS.
